Baxter International (BAX) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Baxter International (NYSE: BAX):

• 5/1/2026 – Baxter International had its price target lowered by TD Cowen from $22.00 to $20.00.
• 5/1/2026 – Baxter International had its price target lowered by Stifel Nicolaus from $20.00 to $19.00.
• 5/1/2026 – Baxter International had its price target raised by The Goldman Sachs Group, Inc. from $17.00 to $19.00.
• 5/1/2026 – Baxter International had its price target raised by Barclays PLC from $25.00 to $27.00. They now have an “overweight” rating on the stock.
• 4/24/2026 – Baxter International was downgraded by Zacks Research from “hold” to “strong sell”.
• 4/6/2026 – Baxter International had its price target lowered by Evercore Inc from $23.00 to $22.00. They now have an “outperform” rating on the stock.

Baxter International Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Friday, May 29th will be paid a dividend of $0.01 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s payout ratio is currently -1.88%.

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.